Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01092546 · ClinicalTrials.gov registry record · Phase 3
Positron Emission Tomography Imaging of Brain Amyloid in Normal Pressure Hydrocephalus
A Phase 3 study, sponsored by GE Healthcare.
- Terminated
- Registry status
- Phase 3
- Development phase
- 12
- Enrollment target
NCT01092546 is a Phase 3 study that was terminated before completion, run by GE Healthcare. The registered enrollment target is 12 participants.
The verdict
NCT01092546, a Phase 3 study, was terminated before completion, sponsored by GE Healthcare.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 12 participants
- Enrollment target
Study Summary
To determine the level of association between the quantitative estimates of brain uptake of \[18F\]flutemetamol and the quantitative immunohistochemical and histochemistry estimates of amyloid levels in frontal lobe biopsy samples obtained from subjects during shunt placement for NPH.
Interventions
- DRUG [18F]Flutemetamol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2010-03 |
| Est. Completion | 2011-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01092546
The ClinicalTrials.gov registry entry for NCT01092546 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GE Healthcare, which has 99 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [18F]Flutemetamol is the first listed.
NCT01092546 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01092546 about?
NCT01092546 is a clinical study titled "Positron Emission Tomography Imaging of Brain Amyloid in Normal Pressure Hydrocephalus". To determine the level of association between the quantitative estimates of brain uptake of \[18F\]flutemetamol and the quantitative immunohistochemical and histochemistry estimates of amyloid levels in frontal lobe biopsy samples obtained from subjects during shunt placement for NPH.
What is the current status of trial NCT01092546?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 12 participants. The study started on 2010-03. Estimated completion is 2011-04.
What interventions are being tested in trial NCT01092546?
The interventions under investigation include: [18F]Flutemetamol (DRUG).
Who is sponsoring clinical trial NCT01092546?
This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.